Online inquiry

IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2438MR)

This product GTTS-WQ2438MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TSLP gene. The antibody can be applied in Asthma, Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_033035.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 85480
UniProt ID Q969D9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2438MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14370MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8695MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ15701MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ3110MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ7045MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ12983MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ13722MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ9609MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW